BR9914858A - Inibidores de biosìntese sintase h de endoperóxido de prostaglandina - Google Patents

Inibidores de biosìntese sintase h de endoperóxido de prostaglandina

Info

Publication number
BR9914858A
BR9914858A BR9914858-7A BR9914858A BR9914858A BR 9914858 A BR9914858 A BR 9914858A BR 9914858 A BR9914858 A BR 9914858A BR 9914858 A BR9914858 A BR 9914858A
Authority
BR
Brazil
Prior art keywords
cox
inhibitors
cyclooxygenase
kidneys
biosynthesis inhibitors
Prior art date
Application number
BR9914858-7A
Other languages
English (en)
Inventor
Lawrence A Black
Anwer Basha
Teodozyj Kolasa
Michael E Kort
Huaqing Liu
Catherine M Mccarty
Meena V Patel
Jeffrey J Rohde
Michael J Coghlan
Andrew O Stewart
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Priority claimed from US09/427,768 external-priority patent/US6307047B1/en
Publication of BR9914858A publication Critical patent/BR9914858A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

"INIBIDORES DE BIOSìNTESE SINTASE H DE ENDOPERóXIDO DE PROSTAGLANDINA". A presente invenção descreve compostos de piridazinona da fórmula (I) que são inibidores de ciclooxigenase (COX) e especificamente, são inibidores seletivos de ciclooxigenase-2 (COX-2), COX-2 é a isoforma induzível associada à inflamação, quando oposta à isoforma constitutiva, ciclooxigenase-1 (COX-1) que é uma enzima "organizadora", em muitos tecidos, incluindo o trato gastrointestinal (GI) e os rins. A seletividade destes compostos para COX-2 minimiza os efeitos colaterais em GI e renais indesejados, vistos nos medicamentos anti-inflamatórios não esteróides comercializados correntemente.
BR9914858-7A 1998-10-27 1999-10-27 Inibidores de biosìntese sintase h de endoperóxido de prostaglandina BR9914858A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17960598A 1998-10-27 1998-10-27
US26187299A 1999-03-03 1999-03-03
US29849099A 1999-04-23 1999-04-23
PCT/US1999/025234 WO2000024719A1 (en) 1998-10-27 1999-10-27 Prostaglandin endoperoxide h synthase biosynthesis inhibitors
US09/427,768 US6307047B1 (en) 1997-08-22 1999-10-27 Prostaglandin endoperoxide H synthase biosynthesis inhibitors

Publications (1)

Publication Number Publication Date
BR9914858A true BR9914858A (pt) 2002-02-05

Family

ID=27497355

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914858-7A BR9914858A (pt) 1998-10-27 1999-10-27 Inibidores de biosìntese sintase h de endoperóxido de prostaglandina

Country Status (19)

Country Link
EP (1) EP1124804B1 (pt)
JP (1) JP2003512292A (pt)
KR (1) KR100666838B1 (pt)
CN (1) CN1279026C (pt)
AT (1) ATE302759T1 (pt)
BG (1) BG65261B1 (pt)
BR (1) BR9914858A (pt)
CA (1) CA2347982A1 (pt)
CZ (1) CZ300570B6 (pt)
DE (1) DE69926903T2 (pt)
DK (1) DK1124804T3 (pt)
ES (1) ES2249919T3 (pt)
HK (1) HK1041876B (pt)
HU (1) HUP0105248A3 (pt)
NO (1) NO318623B1 (pt)
PL (1) PL198503B1 (pt)
SK (1) SK286806B6 (pt)
TR (1) TR200101765T2 (pt)
WO (1) WO2000024719A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2324126T3 (es) 1997-11-19 2009-07-30 Kowa Co., Ltd. Derivados de piridazina y medicamentos que los contienen como ingrediente activo.
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
TWI290130B (en) 2000-09-15 2007-11-21 Pharmacia Corp 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
GEP20063937B (en) 2002-02-14 2006-10-10 Pharmacia Corp Substituted pyridinones as modulators of p38 map kinase
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
KR20050113627A (ko) 2003-03-18 2005-12-02 코와 가부시키가이샤 수용성 페닐피리다진 유도체 및 이를 함유하는 의약
JP4354984B2 (ja) 2003-05-07 2009-10-28 オステオロジックス エイ／エス 水溶性ストロンチウム塩を用いる軟骨／骨症状の治療
ES2251866B1 (es) 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP1916240A1 (en) * 2006-10-25 2008-04-30 Syngeta Participations AG Pyridazine derivatives
CN101600458A (zh) 2006-12-22 2009-12-09 瑞蔻达蒂爱尔兰有限公司 采用α2δ配体和NSAID的下泌尿道疾病的联合治疗
DE102007008840A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy)-5-[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007008839A1 (de) * 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4-(3-Hydroxy-3-methyl-butoxy)-5-[4-(methylsulfonyl)phenyl]-2-arylpyridazin-3(2H)-onen
DE102007008843A1 (de) 2007-02-23 2008-08-28 Bayer Healthcare Ag Verfahren zur Herstellung von 4,5-Dihalogen-2-aryl-2H-pyridazin-3-onen
DE102007020689A1 (de) * 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP)
DE102007020690A1 (de) 2007-05-03 2008-11-06 Bayer Healthcare Ag Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP)
DE102007025717A1 (de) * 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
GB0716414D0 (en) * 2007-08-22 2007-10-03 Syngenta Participations Ag Novel insecticides
CA2691782A1 (en) 2007-09-11 2009-03-19 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
JP2012131708A (ja) * 2009-04-28 2012-07-12 Nissan Chem Ind Ltd ４位置換ピリダジノン化合物及びｐ２ｘ７受容体阻害剤
FR2969606B1 (fr) * 2010-12-22 2013-01-11 Pf Medicament Derives de diarylpyridazinones, leur preparation et leur application en therapeutique humaine
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
CN107334767B (zh) * 2017-06-08 2019-03-05 中国医学科学院医药生物技术研究所 一种哒嗪酮类化合物在肿瘤治疗中的应用
WO2021124344A1 (en) * 2019-12-18 2021-06-24 Abida Pyridazine derivatives and their use as cyclooxygenase-2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4238490A (en) * 1979-02-12 1980-12-09 Diamond Shamrock Corporation Antihypertensive pyridazin(2H)-3-ones
BR8108745A (pt) * 1980-08-07 1982-07-06 Diamond Shamrock Corp Difenilpiridazinonas herbicidas e reguladores do crescimento da planta
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
CA2224563A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
ES2224366T3 (es) * 1997-03-14 2005-03-01 MERCK FROSST CANADA & CO. Piridazinonas como inhibidores de ciclooxigenasa-2.
CZ300847B6 (cs) * 1997-08-22 2009-08-26 Abbott Laboratories Arylpyridazinony jako inhibitory biosyntézy prostaglandin endoperoxid H synthasy, jejich použití a farmaceutická kompozice s jejich obsahem
EP1007515A1 (en) * 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
WO1999010332A1 (en) * 1997-08-22 1999-03-04 Abbott Laboratories Prostaglandin endoperoxide h synthase biosynthesis inhibitors

Also Published As

Publication number Publication date
KR20010081101A (ko) 2001-08-27
EP1124804B1 (en) 2005-08-24
DE69926903T2 (de) 2006-07-13
ES2249919T3 (es) 2006-04-01
SK5542001A3 (en) 2001-12-03
DK1124804T3 (da) 2005-12-12
DE69926903D1 (en) 2005-09-29
WO2000024719A1 (en) 2000-05-04
NO20012061L (no) 2001-06-27
CN1342149A (zh) 2002-03-27
TR200101765T2 (tr) 2002-02-21
JP2003512292A (ja) 2003-04-02
HUP0105248A2 (hu) 2002-07-29
CA2347982A1 (en) 2000-05-04
BG65261B1 (bg) 2007-10-31
SK286806B6 (sk) 2009-05-07
PL198503B1 (pl) 2008-06-30
BG105523A (en) 2001-12-29
NO318623B1 (no) 2005-04-18
HUP0105248A3 (en) 2002-09-30
NO20012061D0 (no) 2001-04-26
KR100666838B1 (ko) 2007-01-11
PL349256A1 (en) 2002-07-01
ATE302759T1 (de) 2005-09-15
CZ20011481A3 (cs) 2001-09-12
HK1041876A1 (en) 2002-07-26
HK1041876B (zh) 2006-06-23
CN1279026C (zh) 2006-10-11
EP1124804A1 (en) 2001-08-22
CZ300570B6 (cs) 2009-06-17

Similar Documents

Publication Publication Date Title
BR9914858A (pt) Inibidores de biosìntese sintase h de endoperóxido de prostaglandina
BR9812127A (pt) Arilpiridazinonas como inibidores da biossìntese de prostagleina endoperóxido h sintase
ATE319691T1 (de) Prostaglandin endoperoxyde h synthase biosynthese inhibitoren
Chan et al. Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments
Esser et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2
Velázquez et al. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1, 2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies
Lolli et al. A new class of ibuprofen derivatives with reduced gastrotoxicity
BRPI0011172B8 (pt) derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2
Chen et al. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase
HN2006019068A (es) "sintesis de (r)-n-metilnaltrexona"
Morrison et al. Mechanism of enhanced renal prostaglandin biosynthesis in ureter obstruction. Role of de novo protein synthesis.
Brunell et al. Studies on the metabolism and biological activity of the epimers of sulindac
Renard et al. N-(3-Arylaminopyridin-4-yl) alkanesulfonamides as pyridine analogs of nimesulide: Cyclooxygenases inhibition, anti-inflammatory studies and insight on metabolism
Ramalho et al. The search for new COX-2 inhibitors: a review of 2002–2008 patents
Bhat et al. Novel sulindac derivatives: Synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity
Petrovic et al. Using N, N, N’, N’-tetramethyl-p-phenylenediamine (TMPD) to assay cyclooxygenase activity in vitro
Huguenin et al. Evaluation of the antitumoral potential of different nitric oxide-donating non-steroidal anti-inflammatory drugs (NO-NSAIDs) on human urological tumor cell lines
Zarghi et al. Design and synthesis of new 2-aryl, 3-benzyl-(1, 3-oxazolidine or 1, 3-thiazolidine)-4-ones as selective cyclooxygenase (COX-2) inhibitors
Osmaniye et al. Design, synthesis and biological evaluation of new N‐acyl hydrazones with a methyl sulfonyl moiety as selective COX‐2 inhibitors
Ouellet et al. Detergents profoundly affect inhibitor potencies against both cyclo-oxygenase isoforms
TR200000478T2 (tr) Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar.
BR0306707A (pt) Derivados de 5-(piridin-3-il)-1-azabiciclo[3.2.1]octano, sua preparação e sua aplicação em terapêutica
Rai et al. Synthesis of Some Novel 2‐[2‐(aroyl‐aroxy)‐methyl]‐4‐phenyl‐1, 3‐thiazoles as Potent Anti‐Inflammatory Agents
Dammann Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity
Tavares The effects of meloxicam, indomethacin or NS‐398 on eicosanoid synthesis by fresh human gastric mucosa

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O E 11 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI.C07D 237/14, C07D 237/18, C07D 401/04, C07D 401/06, C07D 405/04, C07D 409/04, A61K 31/50, A61K 31/501, A61P 19/02, A61P 29/00

Ipc: C07D 237/14 (2011.01), A61K 31/50 (2011.01), C07D

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 12A, 13A E 14A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ATE A 21A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.